Wesbanco Bank Inc. Increases Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Posted by George Bondi on Jun 28th, 2026

Wesbanco Bank Inc. lifted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 41.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,000 shares of the biopharmaceutical company’s stock after acquiring an additional 23,000 shares during the period. Wesbanco Bank Inc. owned 0.06% of Catalyst Pharmaceuticals worth $1,956,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in CPRX. Parkside Financial Bank & Trust lifted its holdings in Catalyst Pharmaceuticals by 17.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 469 shares in the last quarter. Oregon Public Employees Retirement Fund grew its holdings in Catalyst Pharmaceuticals by 1.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock valued at $617,000 after buying an additional 472 shares in the last quarter. Lifestyle Asset Management Inc. grew its holdings in Catalyst Pharmaceuticals by 3.4% during the 4th quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock valued at $393,000 after buying an additional 553 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 630 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in shares of Catalyst Pharmaceuticals by 3.2% during the fourth quarter. ProShare Advisors LLC now owns 22,499 shares of the biopharmaceutical company’s stock valued at $525,000 after buying an additional 702 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 0.3%

Shares of CPRX opened at $31.50 on Friday. The company’s fifty day simple moving average is $30.38 and its 200-day simple moving average is $26.20. The company has a market cap of $3.86 billion, a P/E ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $32.56.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CPRX. HC Wainwright downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $35.00 to $31.50 in a report on Thursday, May 28th. Oppenheimer downgraded shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Zacks Research cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings upgraded shares of Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Finally, Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Catalyst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $32.00.

View Our Latest Research Report on CPRX

Catalyst Pharmaceuticals Company Profile

(Free Report)

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).